Director adds 2,710 InspireMD (NSPR) shares in amended Form 4

Rhea-AI Filing Summary

InspireMD director Paul Stuka reported an open-market purchase of 2,710 shares of InspireMD common stock. The transaction occurred on December 9, 2025 at a weighted average price of $1.81 per share, in multiple trades between $1.80 and $1.81. Following this purchase, Stuka directly owned 391,628 shares. The Form 4/A amends a prior filing solely to correct the number of shares shown in one column, with no other changes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stuka Paul

(Last) (First) (Middle)

C/O INSPIREMD, INC.

6303 WATERFORD DISTRICT DRIVE, SUITE 215

(Street)

MIAMI FL 33126

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
InspireMD, Inc. [ NSPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
12/11/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/09/2025		P		2,710(1)	A	$1.81(2)	391,628	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This Form 4/A amends the Form 4 filed on December 11, 2025 solely to correct the number of shares reported in Table I, Column 4. The number of shares reported in Column 5 was correct as originally filed. No other changes have been made.

2. The price reported is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $1.80 to $1.81. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Remarks:

Exhibit 24.1: Power of Attorney

	/s/ Michael Lawless, Attorney-in-Fact for Paul Stuka	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did InspireMD (NSPR) disclose in this Form 4/A?

InspireMD disclosed that director Paul Stuka purchased 2,710 shares of common stock in the open market. The transaction took place on December 9, 2025 at a weighted average price of $1.81 per share, executed through multiple trades within a narrow price range.

At what price did Paul Stuka buy InspireMD (NSPR) shares on December 9, 2025?

Paul Stuka bought InspireMD shares at a weighted average price of $1.81 per share. The trades occurred in multiple transactions, with individual prices ranging from $1.80 to $1.81, reflecting small variations within a tight band during that trading session.

How many InspireMD (NSPR) shares does Paul Stuka own after this Form 4/A transaction?

After the reported purchase, Paul Stuka directly owns 391,628 shares of InspireMD common stock. This total reflects his holdings following the 2,710-share open-market transaction on December 9, 2025, as shown in the post-transaction ownership column of the Form 4/A filing.

Why was this InspireMD (NSPR) Form 4/A filed as an amendment?

The Form 4/A was filed to correct the number of shares reported in Table I, Column 4 of the original Form 4. The filing states that Column 5, showing post-transaction holdings, was correct initially, and no other changes were made to the prior report.

What does the price range in the InspireMD (NSPR) Form 4/A footnote mean?

The footnote explains that the reported price is a weighted average across several trades. Individual transactions occurred at prices between $1.80 and $1.81 per share, and the reporting person offers to provide full trade-by-trade details upon request to interested parties or regulators.